Comparison of emissions across tobacco products: A slippery slope in tobacco control.

Autor: El-Hellani A; Division of Environmental Health Sciences, College of Public Health, The Ohio State University, Columbus, United States.; Center for Tobacco Research, The Ohio State University Comprehensive Cancer Center, Columbus, United States., Adeniji A; Division of Environmental Health Sciences, College of Public Health, The Ohio State University, Columbus, United States.; Center for Tobacco Research, The Ohio State University Comprehensive Cancer Center, Columbus, United States., Erythropel HC; Department of Chemical and Environmental Engineering, School of Engineering & Applied Science, Yale University, New Haven, United States.; Yale Center for the Study of Tobacco Product Use and Addiction (YCSTP), Department of Psychiatry, Yale School of Medicine, New Haven, United States., Wang Q; Department of Environmental Medicine, University of Rochester Medical Center, Rochester, United States., Lamb T; Department of Environmental Medicine, University of Rochester Medical Center, Rochester, United States., Mikheev VB; Battelle Public Health Center for Tobacco Research, Battelle Memorial Institute, Columbus, United States., Rahman I; Department of Environmental Medicine, University of Rochester Medical Center, Rochester, United States., Stepanov I; Division of Environmental Health Sciences, School of Public Health, University of Minnesota Twin Cities, Minneapolis, United States.; Masonic Cancer Center, University of Minnesota Twin Cities, Minneapolis, United States., Strongin RM; Department of Chemistry, Portland State University, Portland, United States., Wagener TL; Center for Tobacco Research, The Ohio State University Comprehensive Cancer Center, Columbus, United States.; Department of Internal Medicine, The Ohio State University, Columbus, United States., Brinkman MC; Center for Tobacco Research, The Ohio State University Comprehensive Cancer Center, Columbus, United States.; Division of Epidemiology, College of Public Health, The Ohio State University, Columbus, United States.
Jazyk: angličtina
Zdroj: Tobacco induced diseases [Tob Induc Dis] 2024 Mar 30; Vol. 22. Date of Electronic Publication: 2024 Mar 30 (Print Publication: 2024).
DOI: 10.18332/tid/183797
Abstrakt: In this narrative review, we highlight the challenges of comparing emissions from different tobacco products under controlled laboratory settings (using smoking/vaping machines). We focus on tobacco products that generate inhalable smoke or aerosol, such as cigarettes, cigars, hookah, electronic cigarettes, and heated tobacco products. We discuss challenges associated with sample generation including variability of smoking/vaping machines, lack of standardized adaptors that connect smoking/vaping machines to different tobacco products, puffing protocols that are not representative of actual use, and sample generation session length (minutes or number of puffs) that depends on product characteristics. We also discuss the challenges of physically characterizing and trapping emissions from products with different aerosol characteristics. Challenges to analytical method development are also covered, highlighting matrix effects, order of magnitude differences in analyte levels, and the necessity of tailored quality control/quality assurance measures. The review highlights two approaches in selecting emissions to monitor across products, one focusing on toxicants that were detected and quantified with optimized methods for combustible cigarettes, and the other looking for product-specific toxicants using non-targeted analysis. The challenges of data reporting and statistical analysis that allow meaningful comparison across products are also discussed. We end the review by highlighting that even if the technical challenges are overcome, emission comparison may obscure the absolute exposure from novel products if we only focus on relative exposure compared to combustible products.
Competing Interests: The authors have each completed and submitted an ICMJE form for Disclosure of Potential Conflicts of Interest. The authors declare that they have no competing interests, financial or otherwise, related to the current work. A. El-Hellani, A. Adeniji, H.C. Erythropel, I. Rahman, I. Stepanov, R.M. Strongin, T.L. Wagener, and M.C. Brinkman report that since the initial planning of the work they have received support from the National Institute of Drug Abuse (U54DA046060-01). A. El-Hellani, A. Adeniji, T.L. Wagener and M.C. Brinkman also report that since the initial planning of the work they have received support from the National Cancer Institute (U54CA287392). H.C. Erythropel reports that since the initial planning of the work he has received support from the National Institute of Drug Abuse & FDA CTP (U54DA036151), I. Rahman has received support from the National Cancer Institute (U54CA228110), I. Stepanov has received support from the National Institute on Drug Abuse (U01DA045523), and R.M. Strongin has received support from the National Institute of Health (R01ES025257). A. El-Hellani reports that in the past 36 months he has received payments from the National Institute of Drug Abuse (R01DA052565), I. Stepanov has received payments from the National Institute on Drug Abuse (R01DA048899), National Cancer Institute (P01CA269048 and P01CA217806), and T.L. Wagener and M.C. Brinkman have received payments from the National Cancer Institute (R01CA255563 and R01CA276696), and from FDA Center for Tobacco Products (UC2FD007229).
(© 2024 El-Hellani A. et al.)
Databáze: MEDLINE
Externí odkaz: